Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis

NCT05785715 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

81

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor Decision\_Not Safety Related

Conditions

Ulcerative Colitis

Interventions

DRUG: NX-13 250mg
DRUG: NX-13 750mg
DRUG: NX-13 Placebo

Sponsor

AbbVie